Stockreport

iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC [Yahoo! Finance]

iTeos Therapeutics, Inc.  (ITOS) 
PDF The double-blind, placebo-controlled study aims to compare the combination of belrestotug and dostarlimab against placebo plus pembrolizumab in patients with previously [Read more]